What is Windtree Therapeutics, Inc. (WINT)?

Windtree Therapeutics, Inc. (WINT) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of WINT?

The current price of WINT is $0.00. Prices are updated in real time on Stocks360.

What is WINT's price-to-earnings (PE) ratio?

WINT's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is WINT's market capitalization?

WINT's market capitalization is $20,225.00, placing it in the small-cap tier.

Windtree Therapeutics, Inc. (WINT)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$20.23K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.73

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.11

Avg Volume

N/A

Volume

3.02K

Windtree Therapeutics, Inc. (WINT) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $20.23K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $0.10 2026-10-30 · $0.00 (-99.40%)

Earnings

Most Recent

Nov 25, 2025

EPS $-1.08 vs est. $-54.00

Beat by $52.92

Next Earnings

Nov 26, 2026

EPS estimate $-13500.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company re…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	-0.00×
PEG	0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	-0.31×
EV / Sales	0.00×
Earnings Yield	-241955638.86%
Free Cash Flow Yield	-44642.77%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$12.74M
Net Income (TTM)	-$48.94B
Free Cash Flow (TTM)	-$8.66M
Net Debt	$12.72M
Working Capital	-$14.70M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	967.64%
Return on Invested Capital	-323.83%